0000910638-25-000016
SEC filingRevenue declined 16.3% YoY driven by lower materials volume and Geomagic divestiture, partially offset by restructuring savings and a large gain on sale.
For the three months ended June 30, 2025, total revenue declined by 16.3% to $94.8 million from $113.3 million in the prior year period. The decrease was primarily driven by a $17.9 million drop in product revenue, attributed to lower materials volume in dental, service bureaus, and jewelry markets, unfavorable price/mix, and the impact of the Geomagic divestiture. Service revenue also fell $0.5 million. Gross profit declined 23.2% to $36.2 million, with gross margin compressing from 41.6% to 38.1%, as lower volumes and unfavorable mix more than offset cost reductions. Operating loss improved to $15.4 million from $26.4 million, benefiting from a 33.7% reduction in SG&A expenses (driven by restructuring actions, lower compensation, and reduced amortization) and a 21.1% decline in R&D. Non-operating income surged to $132.1 million, largely due to a $125.7 million gain on the Geomagic sale and a $6.6 million gain on debt repurchase, resulting in a net income before tax of $116.8 million.
Healthcare Solutions revenue decreased 7.9% to $45.0 million, driven by a $6.9 million decline in materials revenue (especially dental) partially offset by $2.2 million growth in service revenue from personalized healthcare and parts manufacturing. Gross profit for Healthcare fell 9.2% to $20.4 million, reflecting lower volumes. Industrial Solutions revenue dropped 22.6% to $49.8 million, with declines across product, materials, and service lines. The Geomagic divestiture contributed significantly, while lower materials sales to service bureaus and jewelry markets worsened the trend; aerospace & defense showed strength. Industrial gross profit slumped 36.1% to $15.8 million, impacted by unfavorable price/mix, lower volumes, and the divestiture.
Management highlighted the 2025 Restructuring Plan, authorized in March and augmented in May, targeting $11-$20 million in pre-tax costs by Q2 2026, primarily cash charges, to streamline infrastructure and improve profitability. The Geomagic divestiture closed on April 1, 2025, providing $119.4 million in cash. An interim goodwill impairment test for Healthcare was performed but no impairment was recognized; however, future tests remain sensitive to operating results and market conditions. No specific quantitative guidance was provided, but the company expects cash on hand and available liquidity to meet near-term obligations.
As of June 30, 2025, the company held $116.4 million in cash and cash equivalents, a decrease from $171.3 million at December 31, 2024. Total debt stood at $122.6 million, down from $212.0 million, reflecting the repurchase of $179.7 million of the 0% convertible senior notes due 2026, partially offset by the issuance of $92.0 million of 5.875% convertible senior secured notes due 2030. Shareholders' equity increased to $241.2 million from $176.2 million, driven by net income and other comprehensive income. Inventory rose to $132.9 million from $118.5 million. Total contract liabilities (deferred revenue and customer deposits) were $43.0 million, up from $34.3 million.
Purchase commitments under agreements with remaining terms in excess of one year totaled $19.8 million as of June 30, 2025, primarily related to printer assemblies, inventory, capital expenditures, and software licenses. Of this amount, $10.3 million is expected to be due within the next twelve months. The company also has a $0.8 million standby letter of credit as security for a long-term real estate lease, with a maturity date in June 2026. Additionally, a $5.1 million suspended penalty balance remains under the DDTC settlement agreement, which may be reduced by remedial compliance expenditures.
During the six months ended June 30, 2025, the company repurchased 8.0 million shares of common stock for $14.96 million, executed concurrently with the issuance of the 2030 Notes. No dividends were declared or paid. The company issued $92.0 million of 5.875% convertible senior secured notes due 2030 and used the proceeds, along with $78.0 million of cash on hand, to repurchase $179.7 million of its outstanding 2026 Notes, resulting in a gain on debt extinguishment of $8.2 million. Capital expenditures totaled $5.7 million, representing 3.0% of total revenue.
The company reports two segments: Healthcare Solutions and Industrial Solutions. For the six months ended June 30, 2025, Healthcare Solutions generated $86.3 million in revenue (down 8.5% YoY) and $36.4 million in gross profit (42.2% margin). Industrial Solutions generated $103.0 million in revenue (down 15.4% YoY) and $32.4 million in gross profit (31.5% margin). Geographically, Americas contributed $107.3 million (56.6% of total), EMEA $66.6 million (35.2%), and APAC $15.6 million (8.2%) for the six-month period. One customer accounted for 10.8% of consolidated revenue.
Net income before redeemable non-controlling interest was $67.5M for H1 2025, yet operating cash flow was -$59.6M, a stark divergence. The primary driver was a $125.8M gain on disposition of businesses and assets, which boosted net income but was a non-cash item. Excluding this, core operating cash generation was weak. Working capital consumed $10.1M (accounts receivable +$9.4M, inventories -$11.1M, accounts payable -$8.1M). Capex of $5.7M was modest, representing only 9.6% of the negative CFO. Free cash flow (CFO minus capex) was -$65.3M, insufficient to cover $15.0M in share repurchases. The company relied on asset sales ($119.4M proceeds) and borrowings ($92.0M) to fund operations and capital returns. Anomalies include a $8.2M gain on debt extinguishment and $3.1M deferred tax benefit. Overall, cash flow quality is low due to heavy reliance on one-time gains and external financing.